circle

INVESTORS & MEDIA

PRESS RELEASES

  • Webcast
    X Activate. Inhibit. Empower. Changing the Course of Cardiovascular Disease, A Cytokinetics Virtual Investor and Analyst Day
    Jul 15, 2020 5:30 AM EDT

    Activate. Inhibit. Empower. Changing the Course of Cardiovascular Disease, A Cytokinetics Virtual Investor and Analyst Day
    Jul 15, 2020 5:30 AM EDT
  • Webcast
    X Goldman Sachs 41st Annual Global Healthcare Conference
    Jun 10, 2020 4:40 PM EDT

    Goldman Sachs 41st Annual Global Healthcare Conference
    Jun 10, 2020 4:40 PM EDT

Keyword Search

Press Release Archive
Date Title  
July 1, 2020
Cytokinetics to Host Virtual Investor & Analyst Day on July 15, 2020
link
June 8, 2020
Cytokinetics to Participate In Upcoming Investor Conferences
link
May 27, 2020
Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
link
May 8, 2020
FDA Grants Fast Track Designation For Omecamtiv Mecarbil In Heart Failure
link
May 7, 2020
Cytokinetics to Hold Annual Meeting of Stockholders
link
May 6, 2020
Cytokinetics Reports First Quarter 2020 Financial Results
link
April 22, 2020
Cytokinetics to Announce First Quarter Results on May 6, 2020
link
April 14, 2020
Cytokinetics Provides Clinical Trials and Business Update in Response to COVID-19 Pandemic
link
April 8, 2020
Cytokinetics to Participate in the 19th Annual Needham Virtual Healthcare Conference
link
March 30, 2020
Correction: Cytokinetics Announces Baseline Characteristics from GALACTIC-HF at ACC.20/WCC Virtual
link
March 20, 2020
Cytokinetics to Announce Baseline Characteristics from GALACTIC-HF During ACC.20/WCC
link
March 4, 2020
Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
link
March 3, 2020
Cytokinetics Reports Fourth Quarter 2019 Financial Results
link
March 3, 2020
Cytokinetics Announces Preclinical Data for AMG 594 Presented at the Keystone Symposium on Heart Failure
link
February 28, 2020
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
link
February 26, 2020
Amgen, Cytokinetics And Servier Announce Continuation Of GALACTIC-HF Following Planned Interim Analysis
link
February 20, 2020
Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting
link
February 18, 2020
Cytokinetics to Announce Fourth Quarter Results on March 3, 2020
link
February 6, 2020
Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
link
January 22, 2020
Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants
link
January 13, 2020
Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones
link
January 6, 2020
Cytokinetics Announces Start of REDWOOD-HCM, a Phase 2 Clinical Trial of CK-3773274
link